Clinical Trial Update: A Study to Evaluate the Usability of the SB11 PFS in Trial Participants With Wet AMD, Macular Oedema Secondary to RVO, or mCNV [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the usability of the SB11 prefilled syringe (ranibizumab biosimilar) in participants with wet age-related macular degeneration and macu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Branch Retinal Vein Occlusion with Macular Edema
• Central Retinal Vein Occlusion with Macular Edema
• Myopic Choroidal Neovascularization

Drugs mentioned

• SB11 (ranibizumab)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Age-Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema | Phase 2 | Status: COMPLETED